Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paola Favuzza

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
NPJ Vaccines|February 7, 2020
Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against <i>Plasmodium falciparum</i> parasites in preclinical in vitro and in vivo modelsMarco Tamborrini, Julia Hauser, Anja Schäfer, et al.
Malaria Journal|March 17, 2016
Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPAPaola Favuzza, Simon Blaser, Anita M Dreyer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 18, 2012
Passive immunoprotection of Plasmodium falciparum-infected mice designates the CyRPA as candidate malaria vaccine antigenAnita M Dreyer, Hugues Matile, Petros Papastogiannidis, et al.
BMC Biotechnology|November 24, 2016
Generation of monoclonal antibodies against native viral proteins using antigen-expressing mammalian cells for mouse immunizationNatalie Rose, Carlos Augusto Pinho-Nascimento, Alessia Ruggieri, et al.
Chemmedchem|July 30, 2022
Substrate Peptidomimetic Inhibitors of P. falciparum Plasmepsin X with Potent Antimalarial ActivityLachlan W Richardson, Trent D Ashton, Madeline G Dans, et al.
Elife|February 15, 2017
Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibodyPaola Favuzza, Elena Guffart, Marco Tamborrini, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 21, 2025
Translation of a Human-Based Malaria-on-a-Chip Phenotypic Disease Model for In Vivo ApplicationsMichael J Rupar, Hannah M Hanson, Brianna L Botlick, et al.
Bioorganic Chemistry|August 28, 2021
Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activityBrodie L Bailey, William Nguyen, Anna Ngo, et al.
Structure (London, England : 1993)|April 23, 2022
Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivaxAnthony N Hodder, Janni Christensen, Stephen Scally, et al.
ACS Medicinal Chemistry Letters|November 17, 2022
The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of MalariaManuel de Lera Ruiz, Paola Favuzza, Zhuyan Guo, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
NPJ Vaccines|February 7, 2020
Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against <i>Plasmodium falciparum</i> parasites in preclinical in vitro and in vivo modelsMarco Tamborrini, Julia Hauser, Anja Schäfer, et al.
Malaria Journal|March 17, 2016
Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPAPaola Favuzza, Simon Blaser, Anita M Dreyer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 18, 2012
Passive immunoprotection of Plasmodium falciparum-infected mice designates the CyRPA as candidate malaria vaccine antigenAnita M Dreyer, Hugues Matile, Petros Papastogiannidis, et al.
BMC Biotechnology|November 24, 2016
Generation of monoclonal antibodies against native viral proteins using antigen-expressing mammalian cells for mouse immunizationNatalie Rose, Carlos Augusto Pinho-Nascimento, Alessia Ruggieri, et al.
Chemmedchem|July 30, 2022
Substrate Peptidomimetic Inhibitors of P. falciparum Plasmepsin X with Potent Antimalarial ActivityLachlan W Richardson, Trent D Ashton, Madeline G Dans, et al.
Elife|February 15, 2017
Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibodyPaola Favuzza, Elena Guffart, Marco Tamborrini, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 21, 2025
Translation of a Human-Based Malaria-on-a-Chip Phenotypic Disease Model for In Vivo ApplicationsMichael J Rupar, Hannah M Hanson, Brianna L Botlick, et al.
Bioorganic Chemistry|August 28, 2021
Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activityBrodie L Bailey, William Nguyen, Anna Ngo, et al.
Structure (London, England : 1993)|April 23, 2022
Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivaxAnthony N Hodder, Janni Christensen, Stephen Scally, et al.
ACS Medicinal Chemistry Letters|November 17, 2022
The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of MalariaManuel de Lera Ruiz, Paola Favuzza, Zhuyan Guo, et al.
Pageof 2